Biosimilars Market - 2026-2035

July 2026 | 37 pages | ID: BD30FA10C9A3EN
DataM Intelligence

Abstracts

Biosimilars Market reached US$34.57 billion in 2025 and is expected to reach US$ 129.29 billion by 2035, growing with a CAGR of 14.10% during the forecast period 2026-2035.

The Biosimilars Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.

A Biosimilars Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.

By Drug Class

• Monoclonal Antibodies (mAbs)*
• Tumor Necrosis Factor-Alpha (TNF-?) Inhibitors
• Granulocyte Colony-Stimulating Factor (G-CSF)
• Insulin
• Erythropoietin
• Human Growth Hormone
• Follitropin
• Interferons
• Anti-Vascular Endothelial Growth Factor
• Other Drug Classes

By Therapeutic Area

• Oncology*
• Immunology & Autoimmune Diseases
• Metabolic Diseases (including diabetes)
• Neurology
• Infectious Diseases
• Rare Diseases
• Others

By Manufacturing Modality

• Mammalian Cell-Based Biosimilars*
• Microbial-Based Manufacturing
• Plasma-Derived Manufacturing
• Other Manufacturing Platforms

By Route of Administration

• Intravenous *
• Subcutaneous
• Intramuscular
• Others

By End-User

• Hospitals & Specialty Clinics*
• Infusion Centers
• Specialty Pharmacies
• Others

Regional Analysis for Biosimilars Market:

• North America (U.S., Canada, Mexico)
• Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
• Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
• South America (Colombia, Brazil, Argentina, Rest of South America)
• Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

This Report Covers:

• Go-to-market Strategy.
• Neutral perspective on the market performance.
• Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.
• Customized regional/country reports as per request and country level analysis.
• Potential & niche segments and regions exhibiting promising growth covered.
• Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Research Process:

Both primary and secondary data sources have been used in the global Biosimilars Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Contents

1. DEFINITION AND OVERVIEW

1.1. Study Objectives
1.2. Market Definition
1.3. Market Scope
1.4. Stakeholder Analysis
1.5. Currency Considered
1.6. Study Period

2. EXECUTIVE SUMMARY

2.1. Key Takeaways
2.2. Top To Bottom Analysis
2.3. Market Share Analysis
2.4. Data Points from Key Primary Interviews
2.5. Data Points from Key Secondary Databases
2.6. Market Snapshot
2.7. Geographical Snapshot

3. DYNAMICS

3.1. Impacting Factors
  3.1.1. Drivers
    3.1.1.1. Government-Led Switching and Tender Policies Accelerating Biosimilars Adoption in Public Health Systems
    3.1.1.2. Patent Expiry Wave of Blockbuster Biologics Unlocking Multi-Billion-Dollar Biosimilars Entry Windows
    3.1.1.3. Hospital and Payer Cost-Containment Programs Prioritizing Biosimilars in Treatment Protocols
  3.1.2. Restraints
    3.1.2.1. Interchangeability and Physician Confidence Barriers Slowing Automatic Substitution
    3.1.2.2. High Analytical and Clinical Comparability Costs Limiting New Entrant Participation
    3.1.2.3. Complex Cold-Chain and Bioprocess Manufacturing Requirements Increasing Operational Risk
  3.1.3. Opportunity
    3.1.3.1. Rapid Expansion of Biosimilars in Emerging Therapeutic Segments such as Ophthalmology and Rare Diseases
    3.1.3.2. Strategic Licensing and Co-Development Agreements Between Innovators and Biosimilars Developers
    3.1.3.3. Growth of Local Biomanufacturing Hubs in Asia and Latin America Supporting Export-Oriented Drug Class
  3.1.4. Trends
  3.1.5. Impact Analysis

4. INDUSTRY ANALYSIS

4.1. Porter’s Five Force Analysis – Global Biosimilars
4.2. Geopolitical & Supply Chain Exposure
4.3. Social & Patient-Centric Factors
4.4. Economic Factors
4.5. Pricing Analysis
4.6. Regulatory Analysis
4.7. Go-To-Market (GTM) Strategy
4.8. Innovation & R&D Trends
4.9. Sustainability and ESG Analysis
4.10. Biosimilars Ecosystem Participants
4.11. Buyer Decision Criteria & Adoption Drivers
4.12. DMI Opinion – Strategic Outlook for the Global Biosimilars Market

5. BY DRUG CLASS

5.1. Introduction
  5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  5.1.2. Market Attractiveness Index, By Drug Class
5.2. Monoclonal Antibodies (mAbs)*
  5.2.1. Introduction
  5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Tumor Necrosis Factor-Alpha (TNF-?) Inhibitors
5.4. Granulocyte Colony-Stimulating Factor (G-CSF)
5.5. Insulin
5.6. Erythropoietin
5.7. Human Growth Hormone
5.8. Follitropin
5.9. Interferons
5.10. Anti-Vascular Endothelial Growth Factor
5.11. Other Drug Classes

6. BY THERAPEUTIC AREA

6.1. Introduction
  6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
  6.1.2. Market Attractiveness Index, By Therapeutic Area
6.2. Oncology*
  6.2.1. Introduction
  6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Immunology & Autoimmune Diseases
6.4. Metabolic Diseases (including diabetes)
6.5. Neurology
6.6. Infectious Diseases
6.7. Rare Diseases
6.8. Others

7. BY MANUFACTURING MODALITY

7.1. Introduction
  7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturing Modality
  7.1.2. Market Attractiveness Index, By Manufacturing Modality
7.2. Mammalian Cell-Based Biosimilars*
  7.2.1. Introduction
  7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Microbial-Based Manufacturing
7.4. Plasma-Derived Manufacturing
7.5. Other Manufacturing Platforms

8. BY ROUTE OF ADMINISTRATION

8.1. Introduction
  8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  8.1.2. Market Attractiveness Index, By Route of Administration
8.2. Intravenous *
  8.2.1. Introduction
  8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Subcutaneous
8.4. Intramuscular
8.5. Others

9. BY END-USER

9.1. Introduction
  9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  9.1.2. Market Attractiveness Index, By End-User
9.2. Hospitals & Specialty Clinics*
  9.2.1. Introduction
  9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Infusion Centers
9.4. Specialty Pharmacies
9.5. Others

10. BY REGION

10.1. Introduction
  10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  10.1.2. Market Attractiveness Index, By Region
10.2. North America
  10.2.1. Introduction
  10.2.2. Key Region-Specific Dynamics
  10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturing Modality
  10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
  10.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    10.2.8.1. US
    10.2.8.2. Canada
    10.2.8.3. Mexico
10.3. Europe
  10.3.1. Introduction
  10.3.2. Key Region-Specific Dynamics
  10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturing Modality
  10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
  10.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    10.3.8.1. Germany
    10.3.8.2. UK
    10.3.8.3. France
    10.3.8.4. Russia
    10.3.8.5. Italy
    10.3.8.6. Spain
    10.3.8.7. Norway
    10.3.8.8. Netherlands
    10.3.8.9. Sweden
    10.3.8.10. Denmark
    10.3.8.11. Belgium
    10.3.8.12. Switzerland
    10.3.8.13. Austria
    10.3.8.14. Poland
    10.3.8.15. Finland
    10.3.8.16. Rest of Europe
10.4. Latin America
  10.4.1. Introduction
  10.4.2. Key Region-Specific Dynamics
  10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturing Modality
  10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
  10.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    10.4.8.1. Brazil
    10.4.8.2. Argentina
    10.4.8.3. Rest of Latin America
10.5. Asia-Pacific
  10.5.1. Introduction
  10.5.2. Key Region-Specific Dynamics
  10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturing Modality
  10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
  10.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    10.5.8.1. China
    10.5.8.2. India
    10.5.8.3. Japan
    10.5.8.4. Australia
    10.5.8.5. South Korea
    10.5.8.6. New Zealand
    10.5.8.7. Indonesia
    10.5.8.8. Malaysia
    10.5.8.9. Philippines
    10.5.8.10. Singapore
    10.5.8.11. Thailand
    10.5.8.12. Vietnam
    10.5.8.13. Rest of Asia-Pacific
10.6. Middle East and Africa
  10.6.1. Introduction
  10.6.2. Key Region-Specific Dynamics
  10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturing Modality
  10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  10.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
  10.6.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    10.6.8.1. UAE
    10.6.8.2. Saudi Arabia
    10.6.8.3. South Africa
    10.6.8.4. Israel
    10.6.8.5. Egypt
    10.6.8.6. Turkey
    10.6.8.7. Qatar
    10.6.8.8. Kuwait
    10.6.8.9. Oman
    10.6.8.10. Bahrain
    10.6.8.11. Rest of Middle East and Africa

11. COMPETITIVE LANDSCAPE ANALYSIS

11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
11.4. Partner Identification Analysis
11.5. Investment & Funding Landscape
11.6. Strategic Alliances & Innovation Pipelines

12. COMPANY PROFILES

12.1. Pfizer, Inc.*
  12.1.1. Company Overview
  12.1.2. Product Portfolio
  12.1.3. Revenue Analysis
  12.1.4. Pricing Analysis
  12.1.5. SWOT Analysis
  12.1.6. Recent Developments
    12.1.6.1. Major Deals
    12.1.6.2. M&A
    12.1.6.3. Collaboration
    12.1.6.4. Acquisition
    12.1.6.5. Joint Ventures
    12.1.6.6. Innovations
  12.1.7. Recent News
    12.1.7.1. Events
    12.1.7.2. Conferences
    12.1.7.3. Symposiums
    12.1.7.4. Webinars
12.2. Amgen Inc.
12.3. Novartis AG (Sandoz division)
12.4. Samsung Bioepis Co., Ltd.
12.5. Celltrion, Inc.
12.6. Biocon Limited
12.7. Viatris Inc.
12.8. Teva Pharmaceutical Industries Ltd.
12.9. Boehringer Ingelheim International GmbH
12.10. Merck KGaA
12.11. F. Hoffmann-La Roche Ltd.
12.12. Dr. Reddy’s Laboratories Ltd.
12.13. STADA Arzneimittel AG
12.14. Fresenius Kabi AG
12.15. Apotex Inc. (LIST NOT EXHAUSTIVE)

13. GLOBAL BIOSIMILARS MARKET – RESEARCH METHODOLOGY

13.1. Research Data
  13.1.1. Secondary Data
  13.1.2. Primary Data
  13.1.3. CAGR Analysis
13.2. Market Size Estimation Methodology
  13.2.1. Bottom-Up Approach
  13.2.2. Top-Down Approach
13.3. Market Breakdown & Data Triangulation
13.4. Research Assumptions
13.5. Limitations

14. APPENDIX

14.1. About Us and Services
14.2. Contact Us